Potentiality of oxygen-ozonetherapy to improve the health of aging people

Current Aging Science

Volumn 3, Issue 3, 2010, Pages 177-187

  Bocci, Velio ^a   Zanardi, Iacopo ^a   Travagli, Valter ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Aging; Hormones; Immune system; Longevity genes; Oxidative stress; Oxygen ozone therapy; Telomerase

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE 1; CARNITINE; HUMAN GROWTH HORMONE; INSULIN; IRON; MELATONIN; OMEGA 3 FATTY ACID; OXYGEN; OZONE; PRASTERONE; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; RESVERATROL; SELENIUM; SIRTUIN 1; SIRTUIN 3; TELOMERASE; TESTOSTERONE; UBIQUINONE; ZINC;

AGING; ARTICLE; CAENORHABDITIS ELEGANS; CALORIC RESTRICTION; CIRCADIAN RHYTHM; DROSOPHILA MELANOGASTER; ERYTHROCYTE; EXERCISE; HUMAN; IMMUNE SYSTEM; LEUKOCYTE; LIFESPAN; NONHUMAN; OZONE THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; SACCHAROMYCES CEREVISIAE; THROMBOCYTE;

AGING; HEALTH STATUS; HUMANS; LONGEVITY; OXIDATIVE STRESS; OXYGEN; OZONE; REACTIVE OXYGEN SPECIES;

EID: 78651308625     PISSN: 18746098     EISSN: 18746128     Source Type: Journal    
DOI: 10.2174/1874609811003030177     Document Type: Article

References (131)

1. Mecocci P, Polidori MC, Troiano L, Cherubini A, Cecchetti R, Pini G, et al. Plasma antioxidants and longevity: a study on healthycentenarians. Free Radic Biol Med 2000; 28: 1243-8.
2. Harman D. Aging: a theory based on free radical and radiationchemistry. J Gerontol 1956; 11: 298-300.
3. Harman D. The biologic clock: the mitochondria? J Am Geriatr Soc 1972; 20: 145-7.
4. Ames BN, Shigenaga MK and Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA 1993; 90: 7915-22.
5. Halliwell B. Free radicals and antioxidants: a personal view. NutrRev 1994; 52: 253-65.
6. Hamilton ML, Van Remmen H, Drake JA, Yang H, Guo ZM, Kewitt K, et al. Does oxidative damage to DNA increase with age?Proc Natl Acad Sci USA 2001; 98: 10469-74.
7. Sohal RS. Oxidative stress hypothesis of aging. Free Radic BiolMed 2002; 33: 573-4.
8. Brownlee M. The pathobiology of diabetic complications: aunifying mechanism. Diabetes 2005; 54: 1615-25.
9. Fialkow L, Wang Y and Downey GP. Reactive oxygen and nitrogen species as signaling molecules regulating neutrophilfunction. Free Radic Biol Med 2007; 42: 153-64.
10. Poli G, Schaur RJ, Siems WG and Leonarduzzi G. 4-hydroxynonenal: a membrane lipid oxidation product of medicinalinterest. Med Res Rev 2008; 28: 569-631.
11. Niki E. Lipid peroxidation: physiological levels and dual biologicaleffects. Free Radic Biol Med 2009; 47: 469-84.
12. Galli F. Protein damage and inflammation in uraemia and dialysispatients. Nephrol Dial Transplant 2007; 22: v20-36.
13. Pes GM, Lio D, Carru C, Deiana L, Baggio G, Franceschi C, et al. Association between longevity and cytokine gene polymorphisms. A study in Sardinian centenarians. Aging Clin Exp Res 2004; 16: 244-8.
14. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et al. Stress-dependent regulation of FOXO transcription factors bythe SIRT1 deacetylase. Science 2004; 303: 2011-5.
15. Capri M, Salvioli S, Sevini F, Valensin S, Celani L, Monti D, et al. The genetics of human longevity. Ann NY Acad Sci 2006; 1067: 252-63.
16. Salvioli S, Capri M, Santoro A, Raule N, Sevini F, Lukas S, et al. The impact of mitochondrial DNA on human lifespan: a view fromstudies on centenarians. Biotechnol J 2008; 3: 740-9.
17. Scola L, Lio D, Candore G, Forte GI, Crivello A, Colonna-Romano G, et al. Analysis of HLA-DRB1, DQA1, DQB1 haplotypes inSardinian centenarians. Exp Gerontol 2008; 43: 114-8.
18. Marchegiani F, Marra M, Olivieri F, Cardelli M, James RW, Boemi M, et al. Paraoxonase 1: genetics and activities during aging. Rejuvenation Res 2008; 11: 113-27.
19. Salvioli S, Capri M, Bucci L, Lanni C, Racchi M, Uberti D, et al. Why do centenarians escape or postpone cancer? The role of IGF-1, inflammation and p53. Cancer Immunol Immunother 2009; 58: 1909-17.
20. Lescai F, Blanché H, Nebel A, Beekman M, Sahbatou M, Flachsbart F, et al. Human longevity and 11p15.5: a study in 1321centenarians. Eur J Hum Genet 2009; 17: 1515-9.
21. Lescai F, Marchegiani F and Franceschi C. PON1 is a longevitygene: results of a meta-analysis. Ageing Res Rev 2009; 8: 277-84.
22. Bordone L, Motta MC, Picard F, Robinson A, Jhala US, Apfeld J, et al. Sirt1 regulates insulin secretion by repressing UCP2 inpancreatic beta cells. PLoS Biol 2006; 4: e31.
23. Bordone L and Guarente L. Sirtuins and beta-cell function. Diabetes Obes Metab 2007; 9: 23-7.
24. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, et al. Small molecule activators of sirtuins extendSaccharomyces cerevisiae lifespan. Nature 2003; 425: 191-6.
25. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M, et al. Sirtuin activators mimic caloric restriction and delay ageing inmetazoans. Nature 2004; 430: 686-9.
26. Bass TM, Weinkove D, Houthoofd K, Gems D and Partridge L. Effects of resveratrol on lifespan in Drosophila melanogaster andCaenorhabditis elegans. Mech Ageing Dev 2007; 128: 546-52.
27. Beher D, Wu J, Cumine S, Kim KW, Lu SC, Atangan L, et al. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 2009; 74: 619-24.
28. Pacholec M, Chrunyk BA, Cunningham D, Flynn D, Griffith DA, Griffor M, et al. SRT1720, SRT2183, SRT1460, and resveratrol arenot direct activators of SIRT1. J Biol Chem 2010; 285: 8340-51.
29. Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N, et al. Resveratrol delays age-related deterioration and mimicstranscriptional aspects of dietary restriction without extending lifespan. Cell Metab 2008; 8: 157-68.
30. Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi PP, et al. The p66shc adaptor protein controls oxidative stressresponse and life span in mammals. Nature 1999; 402: 309-13.
31. Trinei M, Giorgio M, Cicalese A, Barozzi S, Ventura A, Migliaccio E, et al. A p53-p66Shc signalling pathway controls intracellularredox status, levels of oxidation-damaged DNA and oxidativestress-induced apoptosis. Oncogene 2002; 21: 3872-8.
32. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffer PJ, et al. Forkhead transcription factor FOXO3a protects quiescentcells from oxidative stress. Nature 2002; 419: 316-2.
33. Nemoto S and Finkel T. Redox regulation of forkhead proteinsthrough a p66shc-dependent signaling pathway. Science 2002; 295: 2450-2.
34. Pandolfi S, Bonafè M, Di Tella L, Tiberi L, Salvioli S, Monti D, et al. p66(shc) is highly expressed in fibroblasts from centenarians. Mech Ageing Dev 2005; 126: 839-44.
35. Rossio JL and Goldstein AL. Immunotherapy of cancer withthymosin. World J Surg 1977; 1: 605-16.
36. No authors listed. Thymus hormones. Br Med J 1977; 1: 1559-60.
37. Trainin N, Pecht M and Handzel ZT. Thymic hormones: inducersand. Immunol Today 1983; 4: 16-21.
38. Effros RB. Ageing and the immune system. Novartis Found Symp 2001; 235: 130-9; discussion 139-45, 146-9.
39. Burns EA. Effects of aging on immune function. J Nutr HealthAging 2004; 8: 9-18.
40. Larbi A, Franceschi C, Mazzatti D, Solana R, Wikby A and Pawelec G. Aging of the immune system as a prognostic factor forhuman longevity. Physiology (Bethesda) 2008; 23: 64-74.
41. Fülöp T, Larbi A, Hirokawa K, Mocchegiani E, Lesourds B, Castle S, et al. Immunosupportive therapies in aging. Clin Interv Aging 2007; 2: 33-54.
42. Weksler ME, Pawelec G and Franceschi C. Immune therapy forage-related diseases. Trends Immunol 2009; 30: 344-50.
43. Hayflick L. The biology of human aging. Am J Med Sci 1973; 265: 432-45.
44. Greider CW and Blackburn EH. Identification of a specifictelomere terminal transferase activity in Tetrahymena extracts. Cell 1985; 43: 405-13.
45. Greider CW and Blackburn EH. The telomere terminal transferaseof Tetrahymena is a ribonucleoprotein enzyme with two kinds ofprimer specificity. Cell 1987; 51: 887-98.
46. Hemann MT, Strong MA, Hao LY and Greider CW. The shortesttelomere, not average telomere length, is critical for cell viabilityand chromosome stability. Cell 2001; 107: 67-77.
47. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity withimmortal cells and cancer. Science 1994; 266: 2011-5.
48. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, et al. Extension of life-span by introduction of telomerase intonormal human cells. Science 1998; 279: 349-52.
49. Lamberts SW, van den Beld AW, and van der Lely AJ. Theendocrinology of aging. Science 1997; 278: 419-24.
50. Buvat J, Shabsigh R, Guay A, Gooren L, Torres LO and Meuleman E. Hormones, metabolism, aging, and men's health. In: Porst H andBuvat J, Eds. Standard Practice in Sexual Medicine. Oxford, UK:Blackwell Publisher 2006; pp. 225-286.
51. Stocco DM and McPhaul M. Physiology of testicularsteroidogenesis. In: Neill JD, Ed. Knobil and Neill's Physiology ofReproduction, 3rd ed. New York: Elsevier 2006; pp. 977-1016.
52. Ghosh D, Griswold J, Erman M and Pangborn W. Structural basisfor androgen specificity and oestrogen synthesis in humanaromatase. Nature 2009; 457: 219-23.
53. Hornsby PJ. Biosynthesis of DHEAS by the human adrenal cortexand its age-related decline. Ann NY Acad Sci 1995; 774: 29-46.
54. Labrie F, Bélanger A, Simard J, Van Luu-The and Labrie C. DHEAand peripheral androgen and estrogen formation: intracinology. Ann NY Acad Sci 1995; 774: 16-28.
55. Majewska MD. Neuronal actions of dehydroepiandrosterone. Possible roles in brain development, aging, memory, and affect. Ann NY Acad Sci 1995; 774: 111-20.
56. Brownlee M. Biochemistry and molecular cell biology of diabeticcomplications. Nature 2001; 414: 813-20.
57. Wei Y, Chen K, Whaley-Connell AT, Stump CS, Ibdah JA and Sowers JR. Skeletal muscle insulin resistance: role of inflammatorycytokines and reactive oxygen species. Am J Physiol Regul IntegrComp Physiol 2008; 294: R673-80.
58. Finch CE. Evolution of the human lifespan and diseases of aging:Roles of infection, inflammation, and nutrition. Proc Natl Acad Sci USA 2009. DOI:10.1073/pnas.0909606106.
59. Hotez PJ, Fenwick A, Savioli L and Molyneux DH. Rescuing thebottom billion through control of neglected tropical diseases. Lancet 2009; 373: 1570-5.
60. Stewart ST, Cutler DM and Rosen AB. Forecasting the effects ofobesity and smoking on U. S. life expectancy. N Engl J Med 2009; 361: 2252-60.
61. Jerrett M, Burnett RT, Pope CA 3rd, Ito K, Thurston G, Krewski D, et al. Long-term ozone exposure and mortality. N Engl J Med 2009; 360: 1085-95.
62. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y and Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcoholusedisorders. Lancet 2009; 373: 2223-33.
63. Zaridze D, Brennan P, Boreham J, Boroda A, Karpov R, Lazarev A, et al. Alcohol and cause-specific mortality in Russia: aretrospective case-control study of 48,557 adult deaths. Lancet 2009; 373: 2201-14.
64. Beaglehole R and Bonita R. Alcohol: a global health priority. Lancet 2009; 373: 2173-4.
65. Lekli I, Ray D and Das DK. Longevity nutrients resveratrol, winesand grapes. Genes Nutr 2009 Sep 4, DOI:10.1007/s12263-009-0145-2.
66. Bordone L and Guarente L. Calorie restriction, SIRT1 and metabolism: understanding longevity. Nat Rev Mol Cell Biol 2005; 6: 298-305.
67. Bordone L, Cohen D, Robinson A, Motta MC, van Veen E, Czopik A, et al. SIRT1 transgenic mice show phenotypes resemblingcalorie restriction. Aging Cell 2007; 6: 759-67.
68. Fontana L, Meyer TE, Klein S and Holloszy JO. Long-term calorierestriction is highly effective in reducing the risk for atherosclerosisin humans. Proc Natl Acad Sci USA 2004; 101: 6659-63.
69. Sinclair DA. Toward a unified theory of caloric restriction and longevity regulation. Mech Ageing Dev 2005; 126: 987-1002.
70. Morgan TE, Wong AM and Finch CE. Anti-inflammatorymechanisms of dietary restriction in slowing aging processes. Interdiscip Top Gerontol 2007; 35: 83-97.
71. Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009; 325: 201-4.
72. Pembrey ME, Bygren LO, Kaati G, Edvinsson S, Northstone K, Sjöström M, et al. Sex-specific, male-line transgenerationalresponses in humans. Eur J Hum Genet 2006; 14: 159-66.
73. Victor VM, McCreath KJ and Rocha M. Recent progress inpharmacological research of antioxidants in pathological conditions:cardiovascular health. Recent Pat Antiinfect Drug Discov 2006; 1: 17-31.
74. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of itsphysiological interactions. Endocr Rev 1991; 12: 151-80.
75. Maestroni GJ. Therapeutic potential of melatonin inimmunodeficiency states, viral diseases, and cancer. Adv Exp MedBiol 1999; 467: 217-26.
76. Maestroni GJ. The immunotherapeutic potential of melatonin. Expert Opin Investig Drugs 2001; 10: 467-76.
77. Seeman TE and Robbins RJ. Aging and hypothalamic-pituitaryadrenalresponse to challenge in humans. Endocr Rev 1994; 15: 233-60.
78. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, et al. Effects of human growth hormone in men over60 years old. N Engl J Med 1990; 323: 1-6.
79. Liu H, Bravata DM, Olkin I, Nayak S, Roberts B, Garber AM, et al. Systematic review: the safety and efficacy of growth hormone inthe healthy elderly. Ann Intern Med 2007; 146: 104-15.
80. Zs-Nagy I. Is consensus in anti-aging medical intervention anelusive expectation or a realistic goal? Arch Gerontol Geriatr 2009; 48: 271-5.
81. Bilger B. Forever young. Sciences 1995; 35: 26-30.
82. Baulieu EE and Robel P. Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) as neuroactiveneurosteroids. Proc Natl Acad Sci USA 1998; 95: 4089-91.
83. Nair KS, Rizza RA, O'Brien P, Dhatariya K, Short KR, Nehra A, et al. DHEA in elderly women and DHEA or testosterone in elderlymen. N Engl J Med 2006; 355: 1647-59.
84. Maggio M, Ceda GP, Basaria S, Valenti G and Ferrucci L. Dehydroepiandrosterone sulfate has not been substantiated as ananabolic hormone-Reply. Arch Intern Med 2008; 168: 1470.
85. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life inpostmenopausal women. Ann Intern Med 1992; 117: 1016-37.
86. Peterson LR. Estrogen replacement therapy and coronary arterydisease. Curr Opin Cardiol 1998; 13: 223-31.
87. Malik R, Tondwal S, Venkatesh KS and Misra A. Nanoscaffoldmatrices for size-controlled, pulsatile transdermal testosteronedelivery: nanosize effects on the time dimension. Nanotechnology 2008; 19: 435101-1-6.
88. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, et al. Rapamycin fed late in life extends lifespan in geneticallyheterogeneous mice. Nature 2009; 460: 392-5.
89. Stanfel MN, Shamieh LS, Kaeberlein M and Kennedy BK. TheTOR pathway comes of age. Biochim Biophys Acta 2009; 1790: 1067-74.
90. Battino R, Rettici TR and Tominaga T. The solubility of oxygenand ozone in liquids. J Phys Chem Ref Data 1983; 12: 163-78.
91. Alborzfar M, Escande K and Allen SJ. Removal of 3,4-dichlorobut-1-ene using ozone oxidation. Water Res 2000; 34: 2963-70.
92. Pryor WA, Squadrito GL and Friedman M. The cascademechanism to explain ozone toxicity: The role of lipid ozonationproducts. Free Radic Biol Med 1995; 19: 935-41.
93. Bocci V. Ozone. A new medical drug. Dordrecht, The Netherlands:Springer 2005.
94. Bocci V. Scientific and medical aspects of ozone therapy. State ofthe art. Arch Med Res 2006; 37: 425-35.
95. Bocci V and Aldinucci C. Biochemical modifications induced inhuman blood by oxygenationozonation. J Biochem Mol Toxicol 2006; 20: 133-8.
96. Travagli V, Zanardi I, Silvietti A and Bocci V. A physicochemicalinvestigation on the effects of ozone on blood. Int J Biol Macromol 2007; 41: 504-11.
97. Bocci V, Borrelli E, Travagli V and Zanardi I. The ozone paradox:ozone is a strong oxidant as well as a medical drug. Med Res Rev 2009; 29: 646-82.
98. Bocci V, Zanardi I, Michaeli D and Travagli V. Mechanisms ofaction and chemical-biological interactions between ozone and body compartments: a critical appraisal of the differentadministration routes. Curr Drug Ther 2009; 4: 159-73.
99. Travagli V, Zanardi I, Bernini P, Nepi S, Tenori L and Bocci V. Effects of ozone blood treatment on the metabolite profile ofhuman blood. Int J Toxicol 2010; 29: 165-74.
100. Antunes F and Cadenas E. Estimation of H2O2 gradients acrossbiomembranes. FEBS Lett 2000; 475: 121-6.
101. Stone JR and Yang S. Hydrogen peroxide: A signaling messenger. Antioxid Redox Signal 2006; 8: 243-70.
102. Stone JR and Collins T. The role of hydrogen peroxide inendothelial proliferative responses. Endothelium 2002; 9: 231-8.
103. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V and Milner A. A novel method for measuring antioxidant capacity and itsapplication to monitoring the antioxidant status in prematureneonates. Clin Sci 1993; 84: 407-12.
104. Valacchi G and Bocci V. Studies on the biological effects of ozone:11. Release of factors from human endothelial cells. MediatInflamm 2000; 9: 271-6.
105. Sen R and Baltimore D. Inducibility of kappa immunoglobulinenhancer-binding protein Nf-kappa B by a posttranslationalmechanism. Cell 1986; 47: 921-8.
106. Baeuerle PA and Henkel T. Function and activation of NF-kappa Bin the immune system. Annu Rev Immunol 1994; 12: 141-79.
107. Valacchi G and Bocci V. Studies on the biological effects of ozone:10. Release of factors from ozonated human platelets. MediatInflamm 1999; 8: 205-9.
108. Awasthi YC, Ansari GA and Awasthi S. Regulation of 4-hydroxynonenal mediated signaling by glutathione S-transferase. Methods Enzymol 2005; 401: 379-407.
109. Takahashi Y, Takahashi S, Yoshimi T, Miura T, Mochitate K and Kobayashi T. Increases in the mRNA levels of γ-glutamyltransferase and heme oxygenase-1 in the rat lung afterozone exposure. Biochem Pharmacol 1997; 53: 1061-4.
110. Dianzani MU. 4-Hydroxynonenal and cell signalling. Free RadicRes 1998; 28: 553-60.
111. Cheng JZ, Sharma R, Yang Y, Singhal SS, Sharma A, Saini MK, et al. Accelerated metabolism and exclusion of 4-hydroxynonenalthrough induction of RLIP76 and hGST5.8 is an early adaptiveresponse of cells to heat and oxidative stress. J Biol Chem 2001; 276: 41213-23.
112. Yang YS, Sharma R, Sharma A, Awasthi S and Awasthi YC. Lipidperoxidation and cell cycle signaling: 4-hydroxynonenal, a keymolecule in stress mediated signaling. Acta Biochim Pol 2003; 50: 319-36.
113. Petersen DR and Doorn JA. Reactions of 4-hydroxynonenal withproteins and cellular targets. Free Radic Biol Med 2004; 37: 937-45.
114. Poole LB, Karplus PA and Claiborne A. Protein sulfenic acids inredox signaling. Annu Rev Pharmacol Toxicol 2004; 44: 325-47.
115. Markovitch D, Tyrrell RM and Thompson D. Anticipation ofsubsequent demanding exercise increases the expression of haemoxygenase-1 mRNA in human lymphocytes. Stress 2008; 11: 79-82.
116. Wang R. Two's company, three's a crowd: can H2S be the thirdendogenous gaseous transmitter? FASEB J 2002; 16: 1792-8.
117. Nakao A, Sugimoto R, Billiar TR and McCurry KR. Therapeuticantioxidant medical gas. J Clin Biochem Nutr 2009; 44: 1-13.
118. Calabrese EJ, Stanek EJ 3rd, Nascarella MA and Hoffmann GR. Hormesis predicts low-dose responses better than threshold models. Int J Toxicol 2008; 27: 369-78.
119. Calabrese EJ. Getting the dose-response wrong: why hormesisbecame marginalized and the threshold model accepted. ArchToxicol 2009; 83: 227-47.
120. Benson H and Friedman R. Harnessing the power of the placeboeffect and renaming it "remembered wellness". Annu Rev Med 1996; 47: 193-9.
121. Viru A and Tendzegolskis Z. Plasma endorphin species duringdynamic exercise in humans. Clin Physiol 1995; 15: 73-9.
122. Hilbert JE, Sforzo GA and Swensen T. The effects of massage ondelayed onset muscle soreness. Br J Sports Med 2003; 37: 72-5.
123. Michaud K, Matheson K, Kelly O and Anisman H. Impact ofstressors in a natural context on release of cortisol in healthy adulthumans: a meta-analysis. Stress 2008; 11: 177-97.
124. Travagli V, Zanardi I and Bocci V. A realistic evaluation of theaction of ozone on whole human blood. Int J Biol Macromol 2006; 39: 317-20.
125. Bocci V, Borrelli E, Valacchi G and Luzzi E. Quasi-total-bodyexposure to an oxygen-ozone mixture in a sauna cabin. Eur J ApplPhysiol Occup Physiol 1999; 80: 549-54.
126. Werkmeister H. Dekubitalgeschwüre und die Behandlung mit derOzon-Unterdruckbegasung In: Viebahn-Hänsler R and Knoch HG, Eds. Ozon-Handbuch. Grundlagen. Prävention. Therapie. Landsberg: Ecomed 2001; pp. V-7.1 1-V-7.1 22.
127. Thiele JJ, Traber MG, Tsang K, Cross CE and Packer L. In vivoexposure to ozone depletes vitamins C and E and induces lipidperoxidation in epidermal layers of murine skin. Free Radic BiolMed 1997; 23: 385-91.
128. Thiele JJ, Traber MG, Polefka TG, Cross CE and Packer L. Ozoneexposuredepletes vitamin E and induces lipid peroxidation inmurine stratum corneum. J Invest Dermatol 1997; 108: 753-7.
129. Thiele JJ, Hsieh SN, Briviba K and Sies H. Protein oxidation inhuman stratum corneum: susceptibility of keratins to oxidation invitro and presence of a keratin oxidation gradient in vivo. J InvestDermatol 1999; 113: 335-9.
130. Valacchi G, van der Vliet A, Schock BC, Okamoto T, Obermuller-Jevic U, Cross CE, et al. Ozone exposure activates oxidative stressresponses in murine skin. Toxicology 2002; 179: 163-70.
131. He QC, Tavakkol A, Wietecha K, Begum-Gafur R, Ansari SA and Polefka T. Effects of environmentally realistic levels of ozone onstratum corneum function. Int J Cosmet Sci 2006; 28: 349-57.